

Additional data: Adrie et al.

	Baseline after Solvent	NO 1 ppm	NO 5 ppm	NO 10 ppm	NO 20 ppm
PaO ₂ (mmHg)	66 ± 11	85 ± 14*	99 ± 20**	125 ± 22**	102 ± 26**
Q _{VA} /Q _T (%)	49.4 ± 2.1	45 ± 2.2	41.2 ± 3.9*	39.5 ± 3.3**	42.2 ± 3**
LAP (mmHg)	10 ± 1	10 ± 1	10 ± 1	10 ± 1	10 ± 1
CVP (mmHg)	9 ± 1	10 ± 1	10 ± 1	10 ± 1	9 ± 1
PAP (mmHg)	24 ± 1	23 ± 1*	20 ± 1**	20 ± 1*	22 ± 1
PVR (dynes·sec·cm ⁻⁵)	384 ± 56	325 ± 60	250 ± 51*	276 ± 62*	320 ± 47
SAP (mmHg)	85 ± 10	85 ± 8.7	86 ± 12	86 ± 9	82 ± 12
SVR (dynes·sec·cm ⁻⁵)	2111 ± 312	1989 ± 272	2168 ± 446	2160 ± 273	2160 ± 352
CO (l·min ⁻¹)	2.9 ± 0.2	3.2 ± 0.1	3.2 ± 0.3	2.9 ± 0.1	2.9 ± 0.3
cGMP (pmol·ml ⁻¹)	22.7 ± 1.8	30.5 ± 3.5	36.5 ± 2.7*	46 ± 12**	70 ± 22**

Supplemental Table 1. Effect of inhaled NO during solvent infusion on hemodynamics and gas exchange. Second dose response trials after solvent administration (n=5). Absolute value of arterial blood gas tensions (PaO₂), venous admixture (Q_{VA}/Q_T), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3',5'-cyclic monophosphate (n=3). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.

Additional data: Adrie et al.

	Baseline after Zaprinast	NO 1 ppm	NO 5 ppm	NO 10 ppm	NO 20 ppm
PaO ₂ (mmHg)	70 ± 11	69 ± 16	67 ± 14	72 ± 12	71 ± 15
Q _{VA} /Q _T (%)	42.2 ± 4.5	42 ± 2.6	40.5 ± 3.2	44.6 ± 3.2	43.1 ± 4
LAP (mmHg)	10 ± 1	10 ± 1	10 ± 1	10 ± 1	10 ± 1
CVP (mmHg)	10 ± 1	10 ± 1	10 ± 1	10 ± 1	11 ± 1
PAP (mmHg)	19 ± 1	19 ± 1	19 ± 1	18 ± 1	19 ± 1
PVR (dynes·sec·cm ⁻⁵)	190 ± 27	199 ± 24	193 ± 31	171 ± 24	198 ± 32
SAP (mmHg)	81 ± 3	78 ± 5	81 ± 5.5	85 ± 4	79 ± 6
SVR (dynes·sec·cm ⁻⁵)	1512 ± 144	1440 ± 141	1384 ± 144	1424 ± 129	1440 ± 216
CO (l·min ⁻¹)	4 ± 0.2	3.9 ± 0.3	4.1 ± 0.4	4.4 ± 0.4	4.2 ± 0.5
cGMP (pmol·ml ⁻¹)	42.1 ± 7.5	70.8 ± 6.7*	81.4 ± 10.8**	94.5 ± 8.5**	104 ± 8.5**

Supplemental Table 2. Effect of inhaled NO during Zaprinast infusion on hemodynamics and gas exchange. Second dose response trials after Zaprinast administration (n=10). Absolute value of arterial blood gas tensions (PaO₂), venous admixture (Q_{VA}/Q_T), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3',5'-cyclic monophosphate (n=7). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.